Sugi Predict

Sugi Predict / Compounds / SCHEMBL2647765

SCHEMBL2647765

SCHEMBL2647765

CNS(=O)(=O)c1cnc(NC(=O)N(C2CCCCC2)[C@H]2CC[C@H](C)CC2)s1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ CCNE1 P24864 4/20 0.34
▸ CDK2 P24941 4/20 0.34
▸ CDK5 Q00535 4/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ MAPT P10636 2/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ PIK3CG P48736 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ CDK5R1 Q15078 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2647767 1.00 SMN1; SMN2 (0.37) SMN1; SMN2NPC1GAARAB9ACCNE1
SCHEMBL2647969 0.90 SMN1; SMN2 (0.36) SMN1; SMN2NPC1GAARAB9ACCNE1
SCHEMBL2647782 0.89 SMN1; SMN2 (0.38) SMN1; SMN2NPC1GAARAB9ACCNE1
SCHEMBL2647778 0.89 SMN1; SMN2 (0.38) SMN1; SMN2NPC1GAARAB9ACCNE1
SCHEMBL2650700 0.89 LMNA (0.36) SMN1; SMN2NPC1GAARAB9ACCNE1
SCHEMBL2650697 0.89 LMNA (0.36) SMN1; SMN2NPC1GAARAB9ACCNE1
SCHEMBL2648464 0.87 SMN1; SMN2 (0.37) SMN1; SMN2NPC1GAARAB9ACCNE1
SCHEMBL2648470 0.87 SMN1; SMN2 (0.37) SMN1; SMN2NPC1GAARAB9ACCNE1
SCHEMBL2649416 0.87 ALDH1A1 (0.36) SMN1; SMN2NPC1GAARAB9ACCNE1
SCHEMBL2649409 0.87 ALDH1A1 (0.36) SMN1; SMN2NPC1GAARAB9ACCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582769-B2 Dicycloalkyl urea glucokinase activators NOVO NORDISK A/S (DK) 2009-09-01 — — US disclosed
US-7582769-B2 Dicycloalkyl urea glucokinase activators NOVO NORDISK A/S (DK) 2009-09-01 — — US disclosed
US-7582769-B2 Dicycloalkyl urea glucokinase activators NOVO NORDISK A/S (DK) 2009-09-01 — — US disclosed
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-05-07 — — US disclosed
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-05-07 — — US disclosed
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-05-07 — — US disclosed
EP-1904466-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2008-04-02 — — EP disclosed
WO-2007006760-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators GCK, GCKR, UCK2 SMN1; SMN2 4814/4885NPC1 2090/4885GAA 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.